WO2004055210A1 - Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices - Google Patents
Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices Download PDFInfo
- Publication number
- WO2004055210A1 WO2004055210A1 PCT/FR2003/003675 FR0303675W WO2004055210A1 WO 2004055210 A1 WO2004055210 A1 WO 2004055210A1 FR 0303675 W FR0303675 W FR 0303675W WO 2004055210 A1 WO2004055210 A1 WO 2004055210A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- seq
- region
- hcv
- tires
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Definitions
- the invention relates to the treatment of viral or non-viral pathologies in which proteins are involved, the synthesis of which is initiated through an internal ribosome entry site (IRES), of which at least part of the sequence is similar from one IRES to another.
- IRES internal ribosome entry site
- pathologies are notably but not limited to, among viral pathologies, viruses belonging to the Flaviridae family such as hepatitis C virus (HCV), swine fever (CSFV), bovine diarrhea ( BVDV), and among non-viral pathologies, cancers in which certain proteins are involved, such as for example fibroblast growth factors responsible for the neovascularization of developing tumors, the proto-oncogene c-myc etc ...
- the treatment proposed in the invention consists in preventing the binding of the translation initiation factor, eIF3, to RNA constituting the 5 ′ non-coding part of the IRES (Internai Ribosome Entry Site) sequence of viral genomes or of certain genes involved in the abovementioned pathologies, so as to inhibit protein synthesis.
- IRES Internai Ribosome Entry Site
- the subject of the invention is also a method for screening for molecules capable of inhibiting the formation of the complex: sequence of TIRES / eIF3, in particular nucleotides 56 to 92 of domain II of TIRES and the recombinant polypeptide corresponding to the part central (amino acids 185 to 279) of the protein subunit pi 16 (also called pi 10, eIF3b, eIF-3eta (BLAST P55884)) of eIF3.
- sequence of TIRES / eIF3 in particular nucleotides 56 to 92 of domain II of TIRES and the recombinant polypeptide corresponding to the part central (amino acids 185 to 279) of the protein subunit pi 16 (also called pi 10, eIF3b, eIF-3eta (BLAST P55884)) of eIF3.
- the process of research and development of new therapeutic drug discovery molecules requires above all the identification of new targets associated with diseases (protein, RNA or DNA, or their complex) and their validation.
- the identified and validated target is then used in molecular screening tests, which allow the selection of active molecules.
- the target being constituted by a specific sequence of HCV TIRES (domain II) and a recombinant polypeptide derived from the sequence of the subunit pl l6 of eIF3.
- the invention is more particularly described in connection with the treatment of the HCV virus although this also applies to the swine fever virus (CSFV) or that of bovine diarrhea (BVDV). , and this, taking into account the strong homology existing between these viruses belonging to the same family.
- CSFV swine fever virus
- BVDV bovine diarrhea
- the hepatitis C virus has been identified as being responsible for non-A non-B hepatitis developed frequently during chronic malignant pathologies, such as cirrhosis of the liver or hepatocellular carcinoma.
- HCV is transmitted by blood transfusion or blood derivatives.
- the HCV genome is in the form of single-stranded RNA with a size of around 9.4 kb and coding for a single polyprotein consisting of 3,010 amino acids (CHOO et al., 1989).
- HCV messenger TARN is not done by recognition of the cap (or CAP), since the latter is absent (translation called “cap-dependent"), but through an internal ribosome entry site (IRES), positioned at the 5 'untranslated region (5'-UTR) of HCV, between nucleotides 40 and 372 of the HCV sequence (translation known as "cap- independent ") (equivalent to SEQ ID1 according to the invention).
- IRS internal ribosome entry site
- TIRES of HCV is folded in on itself to form three domains or regions, in a loop, respectively regions II (Ha, Ilb), III (ma, IHb, IIIc, Illd, Ille, Illf) and IV as shown in FIG. 1 (ZHAO et al, 2001), TIRES further comprising a start AUG codon.
- the single-stranded RNA of CSFV and BVDV also contains an IRES sequence containing a start AUG codon, the structure of TIRES being similar to that of HCV (FIG. 1).
- the alignment of the sequences consisting of the genome of these three viruses shows a strong homology of the region II of TIRES, in particular of the MRR site (RNA recognition pattern), which tends to suggest that the molecules acting on TIRES of the HCV could also act on that of the CSFV or the BVDV.
- RNA recognition pattern RNA recognition pattern
- the initiation of translation of mRNA begins with the recognition and fixation by TIRES of the 40S ribosomal subunit and of initiation factors, in particular, the initiation factor called "eIF3".
- the initiation factor eIF3 is a multiprotein complex consisting of 10 different subunits such as for example p36, p44, p47, p66, pi 10, pi 16 and pl70. Secondary structure prediction studies have shown that the pi 16 subunit has in its central part, located between amino acids 185 and 279, a recognition pattern for TARN ⁇ - ⁇ - ⁇ - ⁇ - ⁇ - ⁇ . The location of the recognition motif of the pi 16 subunit of eIF3 is represented in FIG. 2. Similarly, the C-terminal part of the p44 subunit also has a similar structure ⁇ - ⁇ - ⁇ - ⁇ - ⁇ - ⁇ , corresponding to a hypothetical MRR.
- RNA binding protein RNA binding protein
- proteins lnRNP or even snRNP proteins binding to single-stranded DNA.
- the central part of the pi 16 subunit is folded in a conformation similar to that of the known MRRs for the conserved amino acids IVVD and TK / RGF / YVE located in leaves 1 and 3 corresponding to the RNP-2 and RNP-1 recognition patterns (see Figure 2).
- the MRR of pi 16 of eIF3 meets the criteria of "putative RNA-binding proteins", its real capacity to fix TARN has never been demonstrated before.
- document FR-A-2 815 358 describes a method of treating hepatitis C which consists in preventing the protein synthesis of HCV by supposed inhibition of the binding of the pi 16 subunit of eIF3 to region III of TIRES.
- the candidate molecules for this inhibition correspond to polypeptides having an affinity with region III of TIRES greater than that of the pi16 subunit of eIF3.
- the polypeptide inhibitors are obtained by screening for pi16 proteins mutated with the IRES sequence of HCV. More precisely, only the central part corresponding to the recognition motif (MRR) is mutated, the polypeptide being capable of binding to the IIIb loop of HCV TIRES with an affinity greater than or equal to that of the non-mutated MRR of pi 16.
- the mutations are introduced into the MRR by random mutagenesis or by targeted mutagenesis according to the phage display technique.
- no indication is given concerning the nucleotide sequence of region III of TIRES capable of interacting with the mutated MRR.
- no results of a possible inhibition are given in the examples. Sizova et al, 1998, showed that eIF3 protected the Illb apical region of TIRES of HCV and CSFV, in particular nucleotides 204, 212, 214, 215 and 220 (see Figure 1, labeled nucleotides ⁇ ), from enzymatic cleavage or chemical changes.
- the document WO 01/44266 also reports the interaction between the pi 16 subunit of the initiation factor eIF3 and the region III of HCV TIRES, more precisely at the level of a domain capable of pairing and defining two sequences. 7 base and 9 base nucleotides, respectively.
- the definition of this minimal motif makes it possible to implement a test to identify compounds capable of competing in the formation of the eIF3-HCV complex.
- document US-A-6,001,990 describes a series of oligonucleotides, selected for their capacity to inhibit the translation of TNA of HCV.
- Toligonucleotide of 28 nucleotides of sequence TAGACGCTTTCTGCGTG AAGACAGTAGT corresponding to the sequence SEQ ID 3 of this document, effectively hybridizes with region II of TIRES of HCV.
- RNA-binding proteins of the MRR family recognize short single-stranded sequences ( ⁇ 10 nt) belonging to a loop in RNA structures of the loop-stem type or to a stem extension. These short fragments integrated into an appropriate structural context are essential for the specific binding of MRRs to messenger RNAs. or premessagers comprising 1000 nucleotides or more. Therefore, it is important to identify the minimum sequence of TIRES of TIRES interacting with the MRR.
- the identification of this minimum sequence makes it possible first of all to understand the mechanism of the interaction, but also to design complementary antisense oligonucleotides (of size generally between 30-35nt) capable of inhibiting the formation of the complex RNA / protein or in the case of RNAi (interference RNA or silencing of size between 21-23 nt) to target the interaction region.
- the identification of the minimum sequence is also essential for carrying out the structural studies necessary for in silico screening as well as for the optimization of active molecules. According to a technique known to those skilled in the art, the atomic structure of the RNA / protein complex or RNA alone in 3 dimensions is sought by NMR.
- RNA fragments of small size (less than 25 nt).
- a second technique corresponds to X-ray crystallography, a technique which can be applied to larger RNA fragments, however limited to 70 nt.
- the crystallography of proteins is not limited by size but can however only be applied to isolated proteins and not to multiprotein complexes, such as eIF3 (deletion).
- one of the problems which the invention proposes to solve is to precisely identify the smallest RNA sequence of TIRES which binds to the MRR of pi 16, so that this sequence can be used in screening methods for molecules of interest (deletion).
- the candidate molecules can be existing or future molecules whose inhibitory properties are tested by screening.
- the invention firstly relates to a method for screening molecules according to which, in vitro: a the pi 16 subunit (SEQ ID4) of the protein eIF3, the nucleotide sequence of region II (SEQ) is incubated together ID2) of TIRES of HCV or any sequence containing at least 10 successive nucleotides of region II (SEQ ID 2) of TIRES of HCV and the molecule to be tested, b / we then detect the possible formation of complex pi 16 / region II IRES , the absence of a complex testifying to the inhibitory capacity of the molecule tested, to inhibit the formation of said complexes, c / the molecules inhibiting the formation of complexes are selected.
- molecule we mean any chemical molecule of synthetic or natural origin, known or future. This term also designates multiprotein complexes such as antibodies, proteins, peptides, ribonucleotides or natural or modified deoxyribonucleotides, and PNA molecules (peptides-nucleic acids).
- the pi16 subunit of eIF3 contains a TARN recognition motif (MRR) located in the central part, more specifically between amino acids 175 and 279 of the sequence SEQ ID4.
- the amino acid sequence of the pi 16 MRR corresponds to the sequence SEQ ID5.
- SEQ ID5 only the sequence of the recognition motif of the pi 16 protein (SEQ ID5) is incubated.
- the MRR polypeptide from pi 16 (SEQ ID5) is preferably produced in recombinant form, in association with a tag facilitating its purification. It can be labeled, during preparation, with radioactive, biotinylated or fluorescent amino acids, making it possible to detect the formation of the protein / RNA complex.
- sequence consensus contains 37 nucleotides located between nucleotides 56 and 92 of the IRES sequence of HCV.
- This sequence can be produced by chemical synthesis or by in vitro transcription, and labeled by radioactivity, biotinylation or fluorescence.
- region II is incubated and corresponds to the consensus nucleotide sequence SEQ ID3 or a sequence comprising at least 8 successive of the sequence SEQ ID 3.
- RNA is an unstable molecule
- the RNA molecule to be incubated according to the invention can be modified in order to increase its stability.
- it can contain phosphorothioate, methylphosphonate, phosphoramidate, acetamidate, carbamate, etc. skeletons.
- It can also contain modified bases, such as 2'-deoxynucleosides, 2 '-O-alkylnucleosides, 2' -fluoro-2 '-deoxynucleosides.
- the incubation is carried out in a buffer solution at room temperature.
- increasing concentrations of molecules to be tested are incubated in order to detect a possibly dose-dependent efficacy.
- the second step of the process consists in detecting the formation of protein / RNA complex. Any detection method known to a person skilled in the art can be implemented. If radiolabelled RNA is used, the RNA / protein / molecule mixture is advantageously filtered through a nitrocellulose membrane, then the detection is done by measuring the radioactivity bound to the membrane, corresponding to the amount of RNA fixed on protein. Alternatively, TARN can be labeled non-radioactively (by example with biotin), incubated with the protein, filtered through a nitrocellulose membrane and revealed using streptavidin or specific antibodies.
- RNA / protein interaction can be used to detect RNA / protein interaction, such as SPA (Scintillation Proximity Assay), FRET (Fluorescence Resonance Energy Transfer), HTRF (Homogeneous Time-Resolved Fluorescence), LANCE (Lanthanide Chelation Excitation), FP (Fluorescence Polarization), FCS (Fluorescence Correlation Spectroscopy), FL (Fluorescence Lifetime Measurements).
- SPA Scintillation Proximity Assay
- FRET Fluorescence Resonance Energy Transfer
- HTRF Homogeneous Time-Resolved Fluorescence
- LANCE Lanthanide Chelation Excitation
- FP Fluorescence Polarization
- FCS Fluorescence Correlation Spectroscopy
- FL Fluorescence Lifetime Measurements
- the purified pi 16 MRR polypeptide is immobilized using antibodies specific for the myc epitope, present in the C-terminal part of the polypeptide, or Ni 2+ chelators, on a 96-well plate impregnated with glitter.
- the radiolabelled consensus RNA is added. A signal is only detected if TARN is attached to the immobilized polypeptide.
- this screening technique was used by the Applicant to study and compare the capacity of 15 different aminoglycosides to dissociate the MRR complex from pi 16 / consensus RNA.
- the screening results according to the invention are correlated with those of additional tests consisting in testing, ex vivo, the influence of the selected molecule on the cap-independent translation (dependent on TIRES) and the translation cap-dependent using a bi-cistronic construction.
- This step can be implemented by any method known to those skilled in the art, in particular by the construction of bicistronic vectors consisting of two luciferases framing the sequence of region II (SEQ ID 2) or any sequence containing at least 10 nucleotides successive of region II (SEQ ID 2), or the consensus sequence (SEQ ID 3) or a flanking sequence comprising at least 8 successive nucleotides of the sequence SEQ ID 3; the first luciferase being translated in a cap-dependent manner and the second in a cap-independent manner or vice versa. Cells are then transfected with the bicistronic vectors and the rate of translation by Dual Luciferase is measured.
- the cells capable of being transfected are chosen in a conventional manner by a person skilled in the art, such as, for example, HeLa cells or even Huh 7 cells.
- the comparison of the results obtained with the screening test proposed by the Applicant and those of the bicistronic tests makes it possible to retain only the molecules capable both of preventing the fixation of pi 16 on the domain II of TIRES in vitro and of inhibiting specifically IRES-dependent translation in a cellular model (ex vivo).
- tobramycin is both capable of dissociating the pi 16/11 complex in vitro at all the concentrations tested and is the most specific inhibitor of the translation controlled by TIRES demonstrates the validity and relevance of the choice of the pi 16 / IRES complex as a screening target.
- the invention also relates to the use of the molecules identified at the end of the screening process described above for the preparation of a medicament intended for the treatment of hepatitis C (HCV), of swine fever (CSFV) , bovine diarrhea (BVDV).
- HCV hepatitis C
- CSFV swine fever
- BVDV bovine diarrhea
- any molecule capable of inhibiting in vitro the binding of the pi 16 protein in particular its recognition motif (MRR) to region II or a sequence containing at least 10 successive nucleotides of region II (SEQ ID 2), in particular a part of region II corresponding to the sequence SEQ ID3 or a sequence comprising at least 8 successive nucleotides of the sequence SEQ ID 3, can be used for the manufacture of a medicament intended for the treatment of hepatitis C (HCV) , swine fever (CSFV), bovine diarrhea (BVDV).
- MRR recognition motif
- SEQ ID 2 sequence containing at least 10 successive nucleotides of region II
- SEQ ID3 in particular a part of region II corresponding to the sequence SEQ ID3 or a sequence comprising at least 8 successive nucleotides of the sequence SEQ ID 3
- HCV hepatitis C
- CSFV swine fever
- BVDV bovine diarrhea
- the Applicant has found that the aminoglycosides, in particular tobramycin, were capable of inhibiting the binding of the MRR of pi 16 to the consensus sequence of the region II of TIRES and that, in addition, this inhibition did not affect cap-dependent translation.
- the invention also relates to the use of aminoglycosides, in particular tobramycin, for the manufacture of a composition intended for the treatment of hepatitis C (HCV), swine fever (CSFV), bovine diarrhea (BVDV).
- aminoglycosides in particular tobramycin
- HCV hepatitis C
- CSFV swine fever
- BVDV bovine diarrhea
- They may also be derivatives of aminoglycosides, in particular derivatives of tobramycin, having improved properties in the pharmaceutical context.
- These aminoglycosides, preferably tobramycin, or their derivatives can be administered in combination with liposomes for better absorption.
- the Taminogroup in position 6 ′ in tobramycin is particularly exposed and can be selectively acetylated and then used to graft other groups.
- the invention therefore also relates to the use of tobramycin analogs, particularly those modified in the 6 'amino position, for the treatment of hepatitis C.
- RNAi containing 19 nucleotides of the sequence SEQ ID 3 (consensus sequence) flanked by UU can be used as a medicament for the treatment of the same pathologies as above.
- the invention therefore also relates to a pharmaceutical composition
- a pharmaceutical composition comprising an antisense oligonucleotide complementary to the sequence SEQ ID 3 or any sequence comprising at least 8 successive nucleotides of the sequence SEQ ID 3, exception of the sequence TAGACGCTTTCT GCGTGAAGACAGTAGT.
- the molecules tested in the screening process can be known molecules such as for example aminoglycosides but also molecules still to be developed.
- the invention also relates to a method for screening a library of molecules in silico consisting of: - to determine the atomic coordinates either of region II of TIRES (SEQ ID 2) of HCV or of any sequence containing at least 10 successive nucleotides of region II (SEQ ID 2) of HCV TIRES, or of the binding sequence specifically to the MRR of the protein PI 16 of eIF3 (SEQ ID 3) or a sequence comprising at least 8 successive nucleotides of the sequence SEQ ID 3, either of the region II complex (SEQ ID 2) or of the specific sequence (SEQ ID 3) with the recognition motif of the protein pi 16 of eIF3 (SEQ ID 5)
- the molecules thus identified can then be tested in the method described above, consisting in detecting RNA / protein complexes in vitro.
- Figure 1 is a representation of the structure of HCV TIRES. This consists of 3 loop domains, II (lia, Ilb), III (Illa, Illb, IIIc, Illd, Ille, Illf) and IV. References ⁇ and ® indicate the nucleotides involved in the binding of eIF3 according to references Sizova et al. (1998) and Kieft et al. (2001), respectively.
- Figure 2 shows the location of the TARN Recognition Pattern in the pi 16 subunit of eIF3 and the prediction of its secondary structure.
- FIG. 3 compares the affinity of the MRR of pi 16 for regions II, Illabc, IlIeflV and the whole of HCV TIRES, measured after retention on nitrocellulose. On the left, a graphic representation of TIRES of HCV makes it possible to locate the different fragments tested.
- FIG. 4 is a diagram showing the principle of the method for producing random sub-fragments of HCV TIRES.
- FIG. 5 is a diagram showing the principle of the selection process of the random sub-fragments specific to the MRR of pi 16 of eIF3 obtained according to the diagram of FIG. 4 (5 A), and the sequences of the transcription matrices and of the primers used (5B).
- FIG. 6 represents the results of alignment of the RNA sequences, selected at the end of the 4 th and 5 th selection / amplification cycles (6A), and the location of the “consensus” sequence (direction orientation) in TIRES of HCV (6B).
- FIG. 7A shows the capacity of the consensus sequence (DOR4-35 and DOR5-4) to inhibit the interaction between IRES and MRR of pi 16, compared with that of TIRES, II, Ilabc, IlIeflV and transfer RNA.
- FIG. 7B shows that the consensus sequence (nt 56-92) has an affinity for the MRR-pl 16 of eIF3 greater than that of the Illa fragment (nt 153-173) and that of the apical part of fragment II (nt 73 -92).
- FIG. 8 represents the capacity of the aminoglycosides to inhibit the binding of the MRR of eIF3 to the consensus sequence of the region II of HCV TIRES.
- FIG. 9 represents the effect of aminoglycosides on cap-dependent and cap-independent translation in cell culture.
- the bicistronic construction, the cloning scheme of which is shown in FIG. 9A, is used for the transient transfection of HeLa cells with 1 ⁇ g of plasmid DNA ( Figure 9B) and 2.5 ⁇ g of pDNA ( Figure 9C).
- Example 1 Demonstration of the capacity of the recognition motif (MRR) of pl16 to bind to the region II of PIRES of HCV
- the amino acid sequence of the recognition motif (MRR) of the pi 16 protein corresponds to the sequence SEQ ID5 located between amino acids 175 and 279 of the sequence SEQ ID4 (corresponding to the sequence of the pi 16 protein).
- the cDNA coding for the MRR is amplified by RT-PCR from DNA extracted from HeLa cells in the presence of the following primers:
- nucleotide sequences are synthesized and cloned, respectively: - a nucleotide sequence corresponding to the totality of TIRES located between nucleotides 40 and 372 of the HCV DNA (b),
- nucleotide sequence corresponding to the Illabc region located between nucleotides 141 and 252 of the DNA of HCV ⁇ ,
- SEQ ID8 ACCGCTAGCCTCCCCTGTGAGGAACTACT
- SEQ ID9 GAAAGCTTTTTTCTTTGAGGTTTAGGATTTGTGCTCATGATG CACG
- the amplified fragment is first cloned into a plasmid pGEM-T then then into pSP-luc + (Promega) between Nhel and Hind III sites.
- the plasmid pSP-IRES-lucH- thus obtained contains TIRES of HCV clone in fusion with the luciferase under control of the promoter SP6.
- the TIRES sequence was aligned and compared to the other IRES sequences deposited in the banks (such as D49374 or AF139594). The identity observed was 96.6%, which corresponds to the average rate of genomic variability of IRES between different strains of HCV.
- oligonucleotides Two overlapping oligonucleotides, the first of which, SEQ ID10, consists of the promoter for T7 polymerase and the nucleotide sequence of the Illa and Illb region (Nt 139-215 of HCV TARN) and the second, SEQ ID11, of the nucleotide sequence of the Illb region and IIIc (Nt 193-252 of HCV TARN) are hybridized in the presence of a Klenow fragment.
- SEQ ID10 consists of the promoter for T7 polymerase and the nucleotide sequence of the Illa and Illb region (Nt 139-215 of HCV TARN)
- SEQ ID11 the nucleotide sequence of the Illb region and IIIc
- the double stranded cDNA fragment obtained is then amplified by PCR in the presence of T7 corresponding to SEQ ID 12: TAATACGACTCACTATAGGG. And of a flanking oligonucleotide whose sequence is as follows: SEQ IDl 3: TAGCAGTCTCGCGGGGGCACG.
- the cDNA corresponding to the IlIeflV region was obtained by PCR amplification of the plasmid pSP- ⁇ IRES-luc + using primers whose nucleotide sequences correspond to those of SP6 (SEQ IDl 4: TATTTAGGTGACACTATAGAAT) and SEQ IDl 3.
- the plasmid pSP- ⁇ IRES-luc + results from the digestion of the plasmid pSP-IRES-luc + by Nhel, the cleavage sites being located between nucleotides 39/40 and 248/249 of TIRES.
- the amplification product SP6 -> SEQ ID13 is then used as a matrix in the in vitro transcription reaction using SP6-polymerase (SP6 MEGAscript, Ambion).
- the cDNA corresponding to the Iiab region was obtained by PCR amplification of the plasmid pSP-IRES-luc + using the primers SP6 (SEQ ID 14) and SEQ ID 15 GTCCTGGTGGCTGCAGGACACTCATAC.
- the amplification product SP6 -> SEQ IDl 5 is then used as a template in the in vitro transcription reaction using SP6-polymerase.
- Radiolabeled RNA fragments are obtained by in vitro transcription of the above-mentioned matrices in the presence of [ ⁇ -32P] UTP.
- the RNA fragments are purified in a 6% acrylamide-urea gel and precipitated.
- the RNA pellets are taken up in 25mM Tris-HCl, pH 7.4.
- TARN was incubated at 65 ° C in the aforementioned buffer for 5-7 min and then slowly cooled to room temperature.
- the renatured RNAs were incubated with increasing concentrations of protein in the same 25mM Tris-HCl buffer, pH 7.4, at room temperature for 5 min.
- the mixture of proteins and RNA is then deposited on a nitrocellulose membrane previously washed with the same buffer.
- the radioactivity of the filter containing the RNA-protein complexes was measured using the MicroBeta Trilux radioactivity counter (PerkinElmer).
- MRR RNA recognition motifs
- SERF Selection of Random Fragments
- TIRES cDNA 2 ug of TIRES cDNA are digested with 5U of Dnase I (Rnase-free, Amersham), at room temperature, for 15 minutes, making it possible to obtain cDNA fragments, the size of which varies between 30 and 100 nucleotides. Blunt ends are generated at the end of the cDNA fragments obtained, by Taq-polymerase at 72 ° C, for 10 minutes in a PCR buffer based on dNTP 1 mMol. Taq-polymerase simultaneously adds additional “dA” residues to the T '3' end of fragments ( Figure 4).
- the recombinant protein MRRpl 16 of eIF3 is purified on a Ni-NTA-agarose column under native conditions (FIG. 5).
- the purified protein is then incubated with the library consisting of the purified RNA fragments obtained above in a 25 mM Tris-HCl buffer, pH 7.4 for 15 min at room temperature.
- the concentration of TARN is, initially equal to 0.2 ⁇ M and that of the protein, equal to 0.8 ⁇ M.
- the protein / RNA mixture is then deposited on a nitrocellulose membrane previously washed with the same buffer.
- the filter containing the RNA-protein complexes is then cut into pieces and TARN is extracted with an SDS solution, 0.1%), sodium acetate 0.3M pH 5.0 for one hour at room temperature.
- the RNA is then recovered by precipitation in tethanol in the presence of tRNA used to facilitate precipitation.
- the RNA pellet is then taken up in 10 ⁇ l of water and subjected to reverse transcription in the presence of the reverse transcriptase "Stratascript" of T oligonucleotide T7 (Stratagene).
- the single-stranded DNA fragments are then amplified by PCR using Toligonucleotide T7 (SEQ ID 14), T oligonucleotide SP6 (SEQ ID 14) and the sequence SEQ ID 16 corresponding to the linker region adjacent to SP6.
- the concentration d RNA in subsequent cycles is equal to 0.058 ⁇ M and that of the protein is regularly reduced from a value of 1.2 ⁇ M in the second cycle to a value of 0.2 ⁇ M in the fifth cycle.
- obtained after the fourth and fifth cycles are cloned into a plasmid pTrcHis2-TOPO (Invitrogen) chosen to facilitate the cloning process in the absence of the T7 promoter.
- the plasmids were purified and sequenced.
- the sequences obtained were aligned with the software assistant Clustal W DNA (Thompson, JDet al CLUSTAL W: improving the sensitivity of progressive multiple sequence aligned through sequence weighting, positions-specific gap penalties and weight matrix choice. (1994) Nucleic Acids Research, 22, 4673-4680) available during e on the PHz Bio-Informatique Lyonnais website.
- 11 clones contain the sequence UACUGUCUUCACGCAGAAAGCGUCUAGCAUGGCGUU corresponding to nucleotides 56 to 92 of the sequence SEQ ID1
- 2 clones contain the sequence CGCCTCATGCCTGGAGAT (nt 61-72 of SEQ IDl) and one clone shows homology with the part 84-90 of SEQ IDl.
- these results identify the region of TIRES 56-92 of sequence TACTGTCTTCACGCAGAAAGCGTCTAGCCATGGCGTT (SEQ ID3) as corresponding to the binding site of MRRpl 16 (FIG. 6B).
- the advantage of the present discovery is to seek to inhibit the binding of the MRR of pi 16 to the consensus sequence SEQ ID 3 of the region II of TIRES to prevent the initiation of translation and consequently protein synthesis by HCV.
- aminoglycosides represent a class of chemical molecules that interact specifically with certain folded RNA molecules, such as 16S ribosomal RNA, ribozymes, and the TAR region of HIV.
- RNA molecules such as 16S ribosomal RNA, ribozymes, and the TAR region of HIV.
- specificity of these molecules with regard to HCV TARN as well as their capacity to inhibit IRES-dependent translation of HCV TIRES has not been previously demonstrated.
- the screening test is carried out as follows.
- the pi 16 MRR and the region II consensus sequence are incubated in the presence of different aminoglycosides.
- the RNA mixture is then deposited on a nitrocellulose membrane under the same conditions as in Example 2.
- the results are shown in FIG. 8.
- the compounds tobramycin and streptomycin inhibit the formation of the RNA-protein complex at all the concentrations tested.
- Tobramycin inhibits 43% of the MRRpl 16/11 complex at a concentration of 20 ⁇ M and 54% at 40 ⁇ M.
- Streptomycin inhibits 25% of the MRRpl 16/11 complex at a concentration of 20 ⁇ M and 36% at 40 ⁇ M In contrast, neomycin and sisomycin only inhibit the complex at concentrations greater than 40 ⁇ M .
- the aminoglycosides kanamycin A, kanamycin B and tobramycin are molecules of very similar structure. However, tobramycin (43% inhibition at 20 ⁇ M) is more active than kanamycin B (22% inhibition at 20 ⁇ M) which is in turn more active than kanamycin A (0% inhibition at 20 , 40 and 80 ⁇ M). This indicates that the presence of an aminogroup in position R2 (tobramycin and kanamycin B) promotes the dissociation of the complex, while the presence of the hydroxyl group in position RI is unfavorable there (kanamycin A) On the other hand, the amino group in position 6 is not directly involved in the interaction and can therefore be used to introduce modifications allowing the necessary active concentrations to be reduced.
- Bicistronic constructs consisting of a first cistron corresponding to the Renilla luciferase gene, followed by the IRES sequence, followed by a second cistron corresponding to the Firefly luciferase gene (pRluc-IRES-Fluc) are prepared as follows.
- a plasmid pRL-SV40 (Promega) is linearized with Xba I and dephosphorylated.
- TIRES is amplified with the Firefly luciferase gene by PCR, in the presence of complementary oligonucleotides containing the Xbal sites.
- the PCR products are then subcloned into the plasmid pTrcHis2-TOPO (Invitrogen) in order to control digestion.
- the Tinsert ligation containing TIRES with the luciferase gene Firefly and the linearized vector pRL-SV40 is carried out using T4 DNA ligase (Biolabs).
- HeLa cells suspended in serum-free DMEM are transfected with 1 to 2.5 ⁇ g of plasmid pRluc-IRES-Fluc by electroporation at 0.5 V for 30 milliseconds using a Méder gene (BioRad).
- the cells are then cultured in 24 or 96-well plates in the presence of different aminoglycosides, at concentrations between 2 and 5 mM for 24-36 hrs.
- tobramycin inhibits the synthesis of Firefly luciferase controlled by TIRES of the hepatitis C virus by 90.4%, while the synthesis of Renilla luciferase, controlled by "cap”, is not inhibited (168% of the control).
- a similar effect is observed at a concentration of tobramycin of 2 mM (the synthesis of IRES-luciferase is inhibited at 83% and that of cap-luciferase is inhibited only at 27%).
- Hygromycin and G418 inhibit both cap-dependent and IRES-dependent translation in an IRES-nonspecific manner.
- streptomycin inhibits the translation of the two cistrons in an IRES-non-specific manner (from 5mM in concentration).
- certain aminoglycosides are capable of inhibiting TIRES-dependent translation in an IRES-specific manner, without inhibiting the translation of the host cell.
- These non-toxic molecules for the cell at the indicated concentrations can be used to treat hepatitis C.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03813166A EP1570089A1 (fr) | 2002-12-12 | 2003-12-11 | Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices |
US10/538,471 US20060035212A1 (en) | 2002-12-12 | 2003-12-11 | Molecules inhibiting hepatitis c virus protein synthesis and method for screening same |
AU2003296819A AU2003296819A1 (en) | 2002-12-12 | 2003-12-11 | Molecules inhibiting hepatitis c virus protein synthesis and method for screening same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0215718A FR2848572B1 (fr) | 2002-12-12 | 2002-12-12 | Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices |
FR02/15718 | 2002-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004055210A1 true WO2004055210A1 (fr) | 2004-07-01 |
Family
ID=32338718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/003675 WO2004055210A1 (fr) | 2002-12-12 | 2003-12-11 | Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060035212A1 (fr) |
EP (1) | EP1570089A1 (fr) |
AU (1) | AU2003296819A1 (fr) |
FR (1) | FR2848572B1 (fr) |
WO (1) | WO2004055210A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005041984A1 (fr) * | 2003-10-31 | 2005-05-12 | Steele Philip M | Compositions et traitements destines a des infections par un virus enveloppe |
PL2666859T3 (pl) * | 2006-04-03 | 2019-09-30 | Roche Innovation Center Copenhagen A/S | Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA |
ES2715625T3 (es) * | 2006-04-03 | 2019-06-05 | Roche Innovation Ct Copenhagen As | Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN |
MX2009003729A (es) * | 2006-10-09 | 2009-04-22 | Santaris Pharma As | Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a. |
EP2126079A1 (fr) * | 2007-03-22 | 2009-12-02 | Santaris Pharma A/S | Composés arn antagonistes pour l'inhibition de l'expression de l'apo-b100 |
DK2149605T3 (da) * | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
CA2697970A1 (fr) * | 2007-08-30 | 2009-03-05 | Santaris Pharma A/S | Composes antagonistes d'arn permettant la modulation de fabp4/ap2 |
JP6035010B2 (ja) * | 2007-10-04 | 2016-11-30 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | マイクロmir |
EP2268811A1 (fr) * | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Compositions pharmaceutiques pour le traitement de maladies associées aux microarn |
US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
WO2010122538A1 (fr) * | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Compositions pharmaceutiques pour le traitement de patients souffrant du vhc ne réagissant pas aux interférons |
WO2011009697A1 (fr) | 2009-07-21 | 2011-01-27 | Santaris Pharma A/S | Oligomères anti-sens ciblant pcsk9 |
EP3591054A1 (fr) | 2013-06-27 | 2020-01-08 | Roche Innovation Center Copenhagen A/S | Oligomères et conjugués antisens ciblant pcsk9 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994023041A2 (fr) * | 1993-04-02 | 1994-10-13 | Ribogene, Inc. | Procede d'inactivation selective de replication virale |
US6001990A (en) * | 1994-05-10 | 1999-12-14 | The General Hospital Corporation | Antisense inhibition of hepatitis C virus |
US6153421A (en) * | 1997-07-18 | 2000-11-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloned genomes of infectious hepatitis C viruses and uses thereof |
WO2001044266A2 (fr) * | 1999-12-16 | 2001-06-21 | Ribotargets Limited | Dosages |
US6284458B1 (en) * | 1992-09-10 | 2001-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
FR2815358A1 (fr) * | 2000-10-17 | 2002-04-19 | Parteurop Dev | Polypeptides inhibiteurs de l'ires du virus de l'hepatite c et procede de criblage desdits polypeptides |
-
2002
- 2002-12-12 FR FR0215718A patent/FR2848572B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-11 AU AU2003296819A patent/AU2003296819A1/en not_active Abandoned
- 2003-12-11 WO PCT/FR2003/003675 patent/WO2004055210A1/fr not_active Application Discontinuation
- 2003-12-11 US US10/538,471 patent/US20060035212A1/en not_active Abandoned
- 2003-12-11 EP EP03813166A patent/EP1570089A1/fr not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6284458B1 (en) * | 1992-09-10 | 2001-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
WO1994023041A2 (fr) * | 1993-04-02 | 1994-10-13 | Ribogene, Inc. | Procede d'inactivation selective de replication virale |
US6001990A (en) * | 1994-05-10 | 1999-12-14 | The General Hospital Corporation | Antisense inhibition of hepatitis C virus |
US6153421A (en) * | 1997-07-18 | 2000-11-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloned genomes of infectious hepatitis C viruses and uses thereof |
WO2001044266A2 (fr) * | 1999-12-16 | 2001-06-21 | Ribotargets Limited | Dosages |
FR2815358A1 (fr) * | 2000-10-17 | 2002-04-19 | Parteurop Dev | Polypeptides inhibiteurs de l'ires du virus de l'hepatite c et procede de criblage desdits polypeptides |
Non-Patent Citations (4)
Title |
---|
BURATTI E ET AL: "FUNCTIONAL ANALYSIS OF THE INTERACTION BETWEEN HCV 5'UTR AND PUTATIVE SUBUNITS OF EUKARYOTIC TRANSLATION INITIATION FACTOR ELF3", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 26, no. 13, 1 July 1998 (1998-07-01), pages 3179 - 3187, XP000993424, ISSN: 0305-1048 * |
CASTROAGUDIN J F ET AL: "Streptococcus bovis bacteremia and endocarditis in patients with liver disease without evidence of colonic pathology.", REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, vol. 88, no. 9, 1996, pages 605 - 608, XP009015917, ISSN: 1130-0108 * |
CHEN P J ET AL: "Molecular biology of hepatitis D virus: research and potential for application.", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. AUSTRALIA OCT 1997, vol. 12, no. 9-10, October 1997 (1997-10-01), pages S188 - S192, XP009015926, ISSN: 0815-9319 * |
SIZOVA D V ET AL: "SPECIFIC INTERACTION OF EUKARYOTIC TRANSLATION INITIATION FACTOR 3 WITH THE 5' NONTRANSLATED REGIONS OF HEPATITIS C VIRUS AND CLASSICAL SWINE FEVER VIRUS RNAS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 6, June 1998 (1998-06-01), pages 4775 - 4782, XP000993423, ISSN: 0022-538X * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
Also Published As
Publication number | Publication date |
---|---|
FR2848572B1 (fr) | 2005-12-09 |
AU2003296819A1 (en) | 2004-07-09 |
FR2848572A1 (fr) | 2004-06-18 |
US20060035212A1 (en) | 2006-02-16 |
EP1570089A1 (fr) | 2005-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10457939B2 (en) | Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules | |
Lee et al. | cis-acting RNA signals in the NS5B C-terminal coding sequence of the hepatitis C virus genome | |
Cammas et al. | Cytoplasmic relocalization of heterogeneous nuclear ribonucleoprotein A1 controls translation initiation of specific mRNAs | |
EP0693126B9 (fr) | Procede d'inactivation selective de replication virale | |
Spångberg et al. | HuR, a protein implicated in oncogene and growth factor mRNA decay, binds to the 3′ ends of hepatitis C virus RNA of both polarities | |
WO2004055210A1 (fr) | Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices | |
JP2003501050A (ja) | 天然型PrPSCを特異的に認識する核酸分子、製造及び使用 | |
KR20140091750A (ko) | 표적 단백질에 결합하는 핵산 단편 | |
JP2005529590A (ja) | ARE含有mRNAとHuRタンパク質の結合のインヒビターの同定方法 | |
US7232807B2 (en) | Compositions and methods for binding agglomeration proteins | |
CA2509494A1 (fr) | Procede d'introduction de sirna dans des adipocytes | |
Florentz et al. | Specific valylation identity of turnip yellow mosaic virus RNA by yeast valyl‐tRNA synthetase is directed by the anticodon in a kinetic rather than affinity‐based discrimination | |
EP3738603A1 (fr) | Inhibiteur de ntcp | |
WO2006016657A1 (fr) | Médicament pour le traitement du vhc ou la prévention de l’infection par vhc | |
Teterina et al. | Strand-specific RNA synthesis defects in a poliovirus with a mutation in protein 3A | |
Fromentin et al. | A method for in vitro assembly of hepatitis C virus core protein and for screening of inhibitors | |
Scarpitti et al. | A noncanonical RNA-binding domain of the fragile X protein, FMRP, elicits translational repression independent of mRNA G-quadruplexes | |
WO2022054801A1 (fr) | ARNsi ET SON UTILISATION | |
AU761012B2 (en) | Vector expressing the full-length gene of RNA virus and use thereof | |
WO2008108521A1 (fr) | Nouvelle utilisation de kiaa0317 en tant que régulateur de l'apoptose | |
US20050261486A1 (en) | Compositions and methods for binding agglomeration proteins | |
JP4265402B2 (ja) | p300ヒストンアセチル化酵素インヒビターを含む転写阻害用組成物及び該p300ヒストンアセチル化酵素インヒビターを阻害し得る阻害物質のスクリーニング方法 | |
US7951928B2 (en) | Gene encoding a protein and preventive/remedy for neurodegenerative diseases such as polyglutamine diseases by utilizing the same | |
Zhu et al. | Nucleolin interacts with the rabbit hemorrhagic disease virus replicase RdRp, nonstructural proteins p16 and p23, playing a role in virus replication | |
Sun | Structural Studies of Viral RNAs and Peptide Targeting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003813166 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006035212 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10538471 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003813166 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10538471 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |